About Enzo
Enzo is a company based in Farmingdale (United States) founded in 1976 was acquired by Battery Ventures in June 2025. Enzo has raised $7 million across 1 funding round from investors including Battery Ventures. The company has 179 employees as of December 31, 2023. Enzo has completed 2 acquisitions, including Asssay Designs and Biomol. Enzo offers products and services including AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA). Enzo operates in a competitive market with competitors including Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
- Headquarter Farmingdale, United States
- Employees 179 as on 31 Dec, 2023
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enzo Biochem Inc
-
Annual Revenue
$32.64 M (USD)-72as on Jul 31, 2022
-
Net Profit
-$26.08 M (USD)-229as on Jul 31, 2024
-
EBITDA
-$11.76 M (USD)52as on Jul 31, 2024
-
Total Equity Funding
$7 M (USD)
in 1 rounds
-
Latest Funding Round
$7 M (USD), Series A
May 19, 2023
- Investors
-
Employee Count
179
as on Dec 31, 2023
-
Investments & Acquisitions
Asssay Designs
& 1 more
-
Acquired by
Battery Ventures
(Jun 24, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enzo
Enzo offers a comprehensive portfolio of products and services, including AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA).
Tools for RNA detection in cells and tissues via in situ hybridization.
Reagents for detecting specific proteins in research applications.
Kits for accurate detection of small and large analytes.
People of Enzo
Unlock access to complete
Funding Insights of Enzo
Enzo has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Series A round of $7 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enzo
Enzo has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Battery Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in technology companies are conducted globally by Battery Ventures.
|
Locked | Locked | Locked |
Investor details for Enzo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enzo
Enzo has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Asssay Designs and Biomol.
Investment portfolio details for Enzo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Online marketplace for reagents, antibodies, and assays is provided.
|
Locked | Locked | 1968 | Locked | |
|
Design services are provided by Asssay Designs in Ann Arbor.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Enzo
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Enzo
Detailed financials for Enzo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enzo Comparisons
Peer comparison for Enzo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enzo
Enzo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Sino Biological, GenScript, Stem Cell Technologies and Miltenyi Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological reagents and antibodies are developed for life science research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Developer of cell culture media and ancillary reagents for life science research
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
|
| Locked | Locked | Locked |
Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders
|
Detailed competitors of Enzo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enzo
Complete news archive for Enzo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enzo
Enzo was founded in 1976 and raised its 1st funding round 47 years after it was founded.
Enzo is headquartered in Farmingdale, United States. It is registered at Farmingdale, New York, United States.
Enzo is a funded company, having raised a total of $7M across 1 funding round to date.
As of Dec 31, 2023, the latest employee count at Enzo is 179.
Annual revenue of Enzo is $32.64M as on Jul 31, 2022.
Enzo Biochem is developing therapeutics, diagnostics, and reagents through its subsidiaries. It is developing therapeutic products through Enzo Therapeutics and focused on gastroenterology, ophthalmology, metabolic and bone disorders and infectious diseases. It has developed technology platforms such as Immune Regulation, gene technology and cell signaling modulation to develop various drugs. It has developed a gene delivery vehicle, the StealthVector. Through its cell signaling platform, it has discovered small molecules to treat cancer and skin disoreders.
Enzo's top competitors include Abcam, Sino Biological and Meridian Bioscience.
Enzo offers AMPIVIEW® RNA Probes, Antibodies, and Immunoassays (ELISA).
Enzo has made 2 acquisitions, including Asssay Designs, and Biomol.
Enzo has 1 investor. Key investors include Battery Ventures.